Literature DB >> 32421810

High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry.

Zara Sayar1, Anna Weatherill1, Stephen Keddie2,3, Jonathan Sive4, Michael P Lunn2,3, Mari Thomas1,5, Shirley D'Sa6.   

Abstract

Arterial and venous thromboses occur in patients with POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein level, and skin changes) syndrome at a previously reported rate of 20%. We reviewed the University College London Hospitals (UCLH) POEMS Registry to determine the rate of venous thromboembolism (VTE), arterial events, and risk factors. This registry, established in 1999 and comprising 103 patients at the time of this study, is the largest single-center cohort in Europe. Of the 83 assessable patients, median age at presentation was 52 years (range, 31-84). Twenty-five patients experienced clinically apparent arterial or venous events, and 2 had concurrent arterial and venous thromboses. Eleven patients had VTEs, including deep vein thrombosis (DVT; 3 of 11), pulmonary embolism (4 of 11), and peripherally inserted central catheter-associated DVT, which occurred during autologous stem cell transplantation (3 of 11). Sixteen patients experienced arterial events: stroke (7 of 16), peripheral arterial occlusion (5 of 16), myocardial infarction (3 of 16), and microvascular disease (1 of 16), with no discernible relationship with thrombocytosis or polycythemia. Thirty percent of POEMS patients have arterial and venous thromboses, higher than previously reported. There were more arterial than venous events, and most occurred during active disease, before the start of chemotherapy, indicating the need for a preemptive approach to thromboprophylaxis.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32421810      PMCID: PMC7252560          DOI: 10.1182/bloodadvances.2020001492

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  10 in total

Review 1.  Acute arterial obliteration: a new feature of the POEMS syndrome?

Authors:  P Lesprit; F J Authier; R Gherardi; L Bélec; D Paris; D Melliere; A Schaeffer; B Godeau
Journal:  Medicine (Baltimore)       Date:  1996-07       Impact factor: 1.889

Review 2.  POEMS syndrome.

Authors:  Stephen Keddie; Michael P Lunn
Journal:  Curr Opin Neurol       Date:  2018-10       Impact factor: 5.710

3.  Coagulation and vascular abnormalities in Crow-Fukase syndrome.

Authors:  K Saida; H Kawakami; M Ohta; K Iwamura
Journal:  Muscle Nerve       Date:  1997-04       Impact factor: 3.217

4.  POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.

Authors:  Angela Dispenzieri
Journal:  Am J Hematol       Date:  2019-05-23       Impact factor: 10.047

5.  Thromboembolic events with lenalidomide-based therapy for multiple myeloma.

Authors:  Smitha Patiyil Menon; S Vincent Rajkumar; Martha Lacy; Patrizia Falco; Antonio Palumbo
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

Review 6.  Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

Authors:  A Palumbo; S V Rajkumar; M A Dimopoulos; P G Richardson; J San Miguel; B Barlogie; J Harousseau; J A Zonder; M Cavo; M Zangari; M Attal; A Belch; S Knop; D Joshua; O Sezer; H Ludwig; D Vesole; J Bladé; R Kyle; J Westin; D Weber; S Bringhen; R Niesvizky; A Waage; M von Lilienfeld-Toal; S Lonial; G J Morgan; R Z Orlowski; K Shimizu; K C Anderson; M Boccadoro; B G Durie; P Sonneveld; M A Hussein
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

7.  Cerebral infarction in POEMS syndrome: incidence, risk factors, and imaging characteristics.

Authors:  S A Dupont; A Dispenzieri; M L Mauermann; A A Rabinstein; R D Brown
Journal:  Neurology       Date:  2009-10-20       Impact factor: 9.910

8.  Arterial thrombosis and thalidomide.

Authors:  Mustafa Goz; M Nesimi Eren; Omer Cakir
Journal:  J Thromb Thrombolysis       Date:  2008-04       Impact factor: 2.300

Review 9.  Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Gary H Lyman; Alok A Khorana; Nicole M Kuderer; Agnes Y Lee; Juan Ignacio Arcelus; Edward P Balaban; Jeffrey M Clarke; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Nigel S Key; Mark N Levine; Howard A Liebman; Margaret A Tempero; Sandra L Wong; Ann Alexis Prestrud; Anna Falanga
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

10.  Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome.

Authors:  Morgane Pihan; Stephen Keddie; Shirley D'Sa; Andrew J Church; Kwee L Yong; Mary M Reilly; Michael P Lunn
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-08-15
  10 in total
  2 in total

1.  Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients.

Authors:  Patrick W Mellors; Taxiarchis Kourelis; Ronald S Go; Eli Muchtar; Morie A Gertz; Shaji K Kumar; Francis K Buadi; Prashant Kapoor; Martha Q Lacy; David Dingli; Yi Hwa; Amie Fonder; Miriam Hobbs; Suzanne Hayman; Rahma Warsame; Nelson R Leung; Yi Lin; Wilson Gonsalves; Mustaqeem Siddiqui; Robert A Kyle; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2021-11-30       Impact factor: 10.047

2.  Cerebrovascular manifestations in hematological diseases: an update.

Authors:  José M Ferro; Joana Infante
Journal:  J Neurol       Date:  2021-02-13       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.